ASTRAZENECA PLC reports

Company Names, identifiers, and filing context for this profile. 1 identity field
Company location
Cambridge
SEC filing record 1 source field available
Fiscal year end
31 December
ASTRAZENECA PLC has filed 2,049 SEC EDGAR filings since 13 Mar 1995

SEC filing history

Showing 151-175 of 1,000 matching filings.

Per page
25
Current page
7
6-K File 001-11960

TEZSPIRE RECOMMENDED FOR APPROVAL IN EU FOR CRSWNP

Filing date
22 Sep 2025
Reporting date
22 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

SAPHNELO MET PRIMARY ENDPOINT IN TULIP-SC

Filing date
17 Sep 2025
Reporting date
17 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON RESOLUTE PHASE III TRIAL

Filing date
17 Sep 2025
Reporting date
17 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Sep 2025
Reporting date
02 Sep 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
28 Aug 2025
Reporting date
28 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
26 Aug 2025
Reporting date
26 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
21 Aug 2025
Reporting date
21 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
18 Aug 2025
Reporting date
18 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
15 Aug 2025
Reporting date
15 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

HOLDING(S) IN COMPANY

Filing date
12 Aug 2025
Reporting date
12 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Aug 2025
Reporting date
01 Aug 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

GEFURULIMAB NANOBODY MET PHASE III ENDPOINTS

Filing date
24 Jul 2025
Reporting date
24 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA PLANS TO INVEST $50BN IN THE US

Filing date
22 Jul 2025
Reporting date
22 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

UPDATE ON ANSELAMIMAB IN AL AMYLOIDOSIS

Filing date
16 Jul 2025
Reporting date
16 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BAXDROSTAT MET PRIMARY ENDPT IN BAXHTN PHIII TRIAL

Filing date
14 Jul 2025
Reporting date
14 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

IMFINZI APPROVED IN THE EU FOR BLADDER CANCER

Filing date
07 Jul 2025
Reporting date
07 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
01 Jul 2025
Reporting date
01 Jul 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
11-K File 001-11960

FORM 11-K

Filing date
26 Jun 2025
Reporting date
31 Dec 2024
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DATROWAY APPROVED IN US FOR EGFRM LUNG CANCER

Filing date
24 Jun 2025
Reporting date
24 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC

Filing date
13 Jun 2025
Reporting date
13 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

DIRECTOR/PDMR SHAREHOLDING

Filing date
12 Jun 2025
Reporting date
12 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

FIXED-DURATION CALQUENCE APPROVED IN EU FOR 1L CLL

Filing date
06 Jun 2025
Reporting date
06 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

BLOCK LISTING INTERIM REVIEW

Filing date
02 Jun 2025
Reporting date
02 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
6-K File 001-11960

TOTAL VOTING RIGHTS

Filing date
02 Jun 2025
Reporting date
02 Jun 2025
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .